Noom moves from weight-loss app to connected metabolic health platform

Noom is pushing deeper into connected care with Noom Band, a wrist-worn wearable designed to feed continuous physiologic data directly into the company’s behavior change platform. The device will track heart rate, heart rate variability, SpO2, sleep and activity, then fold those signals into the Noom app without requiring users to manage a separate consumer wearable ecosystem.

The launch marks a practical expansion of Noom’s metabolic health strategy. The company has already built behavior change tools, telehealth through Noom Med, prescription weight loss medication support and at-home biomarker testing into a broader platform. Wearable data fills a missing layer: what members are doing and how their bodies are responding between clinic touchpoints.

One sentence captures the commercial logic. Noom is betting that more continuous data will translate into better engagement and stronger outcomes.

Continuous physiologic data is now part of the intervention

Noom Band will be bundled into existing enterprise partnerships at no additional upfront cost starting in early 2027, and the wearable will be free for Noom Health employer and health plan customers. Leadership framed the strategy as a way to give payers and employers more measurable value while reducing the friction that often keeps devices from being used consistently.

Geoff Cook, Noom’s chief executive officer, said the company has been missing a major signal: sleep and activity data collected continuously rather than intermittently. Less than 10% of members already use devices such as Oura Ring, Whoop or newer Fitbit models, leaving Noom with a narrow view of day-to-day physiology. A program that aims to change eating, movement and medication use can only do so much when sleep debt, recovery patterns and heart rate trends remain invisible.

By integrating these metrics, Noom is trying to move from episodic coaching to a more responsive model. In obesity care, that matters because weight change is often slow, motivation can fade when the scale stalls, and behavioral interventions work best when they can be adjusted early rather than after months of drift.

Wearable feedback is being tied to weight-loss adherence and sleep gains

Noom is already using internal data to argue that wearables may improve performance inside its programs. An analysis of 144,000 Noom Med members taking a GLP-1 medication found that those who used a connected wearable were 34% more likely to lose 20 pounds by the fourth month in the program. The company also cited a sleep analysis showing that, on average, members on a GLP-1 weight loss drug who used Noom Band slept 90 minutes more per week after two months, while members who started with a sleep deficit added 150 minutes of sleep per week.

Those numbers matter because sleep is not a side issue in metabolic disease. Short sleep and poor sleep quality are linked to insulin resistance, obesity and type 2 diabetes, and they can also make appetite regulation and medication adherence more difficult. A wearable that feeds sleep data into counseling may give clinicians and health coaches a way to identify who needs earlier intervention around routines, recovery and daytime activity.

The device is positioned as an engagement tool as much as a monitoring tool. Noom plans to let members “unlock” the wearable after hitting early program milestones, turning the hardware into a behavioral reward rather than a one-time gadget drop. For a population that often loses steam when progress slows, even small markers of improvement such as steps, recovery and sleep can become substitute wins when the scale plateaus.

Noom is building around its own interpretation layer

Noom chose to develop the device rather than simply partner with an existing wearable brand. Executives said the company wanted control over how the data are interpreted inside the Noom app, instead of forcing users to split attention between two ecosystems competing for the same signal.

The wearable is powered by Sensor Bio, which provides the validated sensors and physiological data layer while Noom manages how the information is translated into interventions. That separation is important. In metabolic health, raw data alone rarely changes behavior; the value lies in whether those measurements can be converted into advice a person can act on the same day.

Cody Fair, Noom Health’s chief commercial officer, said many wearables are built around athletic performance and general wellness. Noom Band is meant to do something more specific: support weight management and cardiometabolic care. The difference is not cosmetic. A device optimized for endurance training may not be the best tool for a person trying to improve A1C, blood pressure and body weight under a structured clinical program.

Employers, payers and CMS are shaping the business case

Noom is marketing the wearable as part of a bundled value proposition for employers and health plans. Expensive devices can erode the return on investment that purchasers expect, and Noom is trying to solve that by including the wearable at no additional cost. The company’s position is blunt: the device should behave like infrastructure, not a premium add-on.

Health plans and employers are looking for evidence within 12 to 24 months, not in an open-ended future. That means Noom will need to show that daily behavioral data can translate into measurable changes in blood pressure, A1C and weight, along with lower downstream cost. The company plans to study whether Noom Band helps produce that return over the next year.

CMS may provide a more formal test case. Noom plans to participate in the agency’s ACCESS Model under the cardio-kidney-metabolic clinical track, with attention to obesity, prediabetes and diabetes improvement. The model is designed as an outcomes-aligned payment structure, and Noom intends to combine the wearable, a blood pressure cuff and its broader behavioral program to maximize the outcomes being measured.

Cook suggested that future wearable technology could go even further, potentially generating a validated blood pressure signal itself and reducing the need for separate devices. For now, the immediate challenge is simpler and harder: prove that a wrist-worn device can improve adherence, sharpen coaching and move clinical endpoints that matter to payers and Medicare.

The biggest unanswered question is not whether the data are useful. It is whether the integration of those data can change long-term cardiometabolic outcomes at a scale that satisfies both members and the organizations paying for care.


Reporting by Dr. A. Nikhil Krishnan, MBBS for Medicine World Foundation, with additional data provided by Fierce Healthcare.